About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

NCT03712969·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

West China Hospital

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age 18 or older;
Pathological diagnosis of patients with stage II, III A primary NSCLC;
R0 resection has been accepted;
Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;
Informed consent has been signed.

You may not be if

Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.);
Patients with unclear pathological types;
Patients with unclear pathological staging;
Preserved Shenlingcao Oral Liquid before R0 resection surgery;
Received immunotherapy or targeted therapy before R0 resection surgery;
Radiotherapy and chemotherapy before R0 resection surgery.

The record

StatusCompleted

PhasePhase 4

Taking part527

StartedNov 2018

UpdatedMay 9, 2024

Conditions

Carcinoma, Non-Small-Cell Lung Chemotherapy, Adjuvant

Where1

Tongji Hospital
Wuhan, Hubei, China

Clareo Health | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC